Veraxa Biotech AG - Post de-SPAC (VRXA) Liabilities and Shareholders Equity (2024 - 2025)
Veraxa Biotech AG - Post de-SPAC's (VRXA) quarterly Liabilities and Shareholders Equity came in at $101.1 million in Q4 2025, up 4.5% year-over-year from $96.8 million in Q4 2024, and up 4.5% quarter-over-quarter from $96.8 million in Q4 2024.
Powered by 
Analysis
Veraxa Biotech AG - Post de-SPAC (VRXA) Liabilities and Shareholders Equity (2024 - 2025) Analysis & Trends
Veraxa Biotech AG - Post de-SPAC (VRXA) has reported Liabilities and Shareholders Equity for 2 consecutive years, with $101.1 million the latest figure, recorded in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 95.64 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 49.36 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 27.42 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 41.73 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 10.03 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 10.96 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 32.09 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 5.31 Bn |
| 10 | Veraxa Biotech AG - Post de-SPAC | 23.88 Mn | 20.47 Mn | - | 101.12 Mn |